Pubblicato il

Medical X-Ray Film Processor Industry Growth, Development and Forecast Report, 2030

The medical X-ray film processor market, valued at USD 1,024.7 million in 2024, is expected to grow to USD 1,238.5 million by 2030, with a compound annual growth rate of 3.2%.

This growth is driven by the increasing prevalence of cancer, dental issues, cardiac conditions, and orthopedic ailments such as arthritis, alongside the rising number of X-ray imaging procedures, growing healthcare expenditures, and heightened awareness of early diagnosis.

In 2021, around 1.2 million heart surgeries were performed globally. Similarly, approximately 850,000 knee replacements are conducted annually in the U.S., reflecting the growing need for X-ray systems for accurate diagnosis due to the increasing incidence of cardiovascular and orthopedic diseases worldwide.

X-ray imaging has significantly improved the early diagnosis and treatment of various conditions, including tumors, bone injuries, pneumonia, and dental problems. This has led to widespread adoption of X-ray imaging systems and, consequently, X-ray films and film processors. As the incidence of these and other ailments rises, the demand for X-ray imaging for diagnosis continues to grow.

In 2023, the fully automatic film processor segment held the largest market share, at 60%, due to its high image quality. The orthopedic segment dominated the market based on application, attributed to the extensive use of X-rays in diagnosing and examining joint or bone conditions such as dislocation, arthritis, and fractures.

The diagnostic centers segment is projected to experience the fastest CAGR in the coming years, driven by the increasing number of diagnostic centers, their accessibility, and their cost-effectiveness compared to full-fledged hospitals.

North America was the largest contributor to the market, with the increasing prevalence of chronic diseases and the growing elderly population boosting the demand for X-ray imaging procedures. The presence of key players, availability of advanced products, and growing awareness of early disease diagnosis are also supporting regional market growth.

The Asia-Pacific region is expected to grow at the fastest rate in the coming years due to rising R&D activities, government initiatives promoting effective and early diagnosis and treatment, improved healthcare infrastructure, increasing demand for advanced medical imaging devices, and a large patient pool.

The rising prevalence of cancer will continue to drive the growth of the medical X-ray film processor market in the future.

Pubblicato il

Increasing Chronic Pain and Smoking Rates Propel Transdermal Drug Delivery Market Growth

The total value of the transdermal drug delivery systems market was USD 4.2 billion in 2023. It is expected to grow at a CAGR of 4.7%, reaching USD 5.8 billion by 2030. This market is primarily driven by the increasing prevalence of chronic illnesses, as traditional drug delivery systems are less effective due to hepatic first-pass metabolism. This process results in oral drugs being mostly broken down in the liver before they can reach their target tissues, reducing their efficacy.

Globally, more than one billion people smoke cigarettes, and despite international and national efforts to monitor, educate, and restrict supply, smoking rates remain high. This drives the demand for transdermal nicotine patches, which have been shown to be 50–60% more effective than placebos in helping individuals quit smoking over a year.

The iontophoresis technology segment leads the market, as it enhances skin penetration and accelerates the release rate of drugs with poor absorption or infusion. The pain management segment is also a major market driver, due to the increasing prevalence of chronic pain from conditions such as amputations, arthritis, and nervous system disorders. An estimated 20% of the global adult population suffers from chronic pain, which significantly impacts productivity and causes emotional and psychological distress. Consequently, transdermal analgesia is gaining popularity.

North America dominates the transdermal drug delivery systems market, driven by patent expirations that allow more companies to enter the market with generic alternatives. Additionally, the relaunch of previously failed drugs for subcutaneous delivery and substantial R&D investments contribute to the region’s significant market share. In Europe, the market is supported by favorable insurance policies and awareness campaigns by government institutions. The region’s advanced healthcare infrastructure and strong public health focus, along with numerous medical device and R&D institutes, facilitate the rapid adoption of innovative healthcare technologies.

The global demand for transdermal drug delivery systems is rising due to the increasing incidence of chronic illnesses, a trend that is expected to continue in the coming years.

Pubblicato il

Genome Editing Industry Size and Forecast Report, 2030

Genome Editing Market

According to P&S Intelligence, the genome editing market is witnessing growth and is projected to reach USD 20,397.8 million by 2030. This is mainly because of the result of the rising pace of technical improvements in the field of genomics, increasing concentration on the extremely adaptable CRISPR technology, and growing expenditure by government and also private establishments in genomics research and development. Moreover, the rising occurrence of many genetic illnesses is projected to drive the industry.

There is an enormous range of prospects in genomics, like agribusiness, drug research, forensics, veterinary sciences, and the identification of human genetic irregularities, that are attaining robust concentration from government and also private biotech agencies. NGS has significantly enhanced genomics’ role in forensics.

Illumina provides various products for studying genetic variations and function. While traditional fingerprint profiling focuses on DNA analysis, the current use of NGS involves analyzing suspect specimens at crime scenes. This enables law enforcement to extract maximum information even from small or damaged DNA samples.

This development can be mainly credited to the rising utilization of cell line engineering in stem cell-based research. Because of the fast improvements, cell line engineering is being widely used for induced pluripotent stem cells, which aid in changing the hereditary content of the cells. The appearance of enhanced gene editing methods, like TALENs, zinc finger nucleases, and CRISPR/Cas, has allowed lucrative and suitable cell engineering.

In recent years, the North American region dominated the market, with a share, of approximately 45%. Furthermore, credited to the growth of gene treatment, increasing use of hereditarily modified harvests, and simple obtainability of research investment, the region will continue the contribute the most significantly to businesses providing tools and facilities for gene editing.

The mounting use of modified drugs is providing huge development opportunities to the companies in the market. With the utilization of a modified drug, a medicinal practitioner is able to identify the exact needs of the patient and offer the exact treatment, accordingly.

Pubblicato il

Over-the-Top Services Market Growth Drivers and Forecast Report, 2030

OTT Services Market

Factors such as the rising internet speed, surging penetration of smart devices and the internet, and burgeoning demand for video-on-demand (VoD) services in developing countries are expected to steer the over-the-top services market growth during the forecast period (2021–2030). Currently, the deployment of the 5G network, to offer increased data speed at low cost, is becoming a prominent market trend. Countries such as the U.S., the U.K., Australia, Japan, Taiwan, Germany, and South Korea have already started deploying 5G networks.

The increasing penetration of the internet and smart devices is one of the key growth drivers for the market globally. Customers can access OTT content through smart TVs, internet-connected phones, tablets, laptops, desktops, gaming consoles, and set-top boxes. Moreover, the increasing amount of time being spent on these smart devices, owing to their escalating use for work and entertainment purposes, will augment the demand for OTT services. Additionally, the growing penetration of high-speed internet and advanced network technologies, such as optical fiber, 4G/LTE, and 5G, will facilitate the market growth.

At present, the OTT services market is fragmented in nature due to the presence of numerous players, such as Netflix Inc., Facebook Inc., Roku Inc., Apple Inc., Amazon.com Inc., Rakuten Inc., The Walt Disney Company, Telstra Corporation Ltd., Google LLC (YouTube), and Kakao Corp. Nowadays, these players are introducing OTT platforms and services to gain a competitive edge. For instance, in March 2021, Netflix Inc. started testing mobile+, a new plan in India for INR 299 per month. This plan will enable subscribers to stream content in 720 HD quality on computers and smartphones. However, this plan will not be accessible on TVs or multiple devices simultaneously.

The monetization model of the OTT services market is classified into advertising-based, subscription-based, and transaction-based. Under this segment, the transaction-based model is expected to witness the fastest growth throughout the forecast period as it enables market players to generate revenue by selling the license of a software product that can be utilized by a group of users or a single user. Moreover, the increasing tendency of users to purchase entire content, such as a full-license video game, with all the features will drive the growth of this category.

Furthermore, the streaming device segment of the OTT services market is categorized into smartphones and tablets, laptops and desktops, gaming consoles, and others. Under this segment, the smartphones and tablets category accounted for the largest market share in 2020 due to the rising technological advancements and growing internet penetration. According to the International Telecommunication Union (ITU), there were 4 billion internet users across the world in 2019. Additionally, this number accounted for over 51% of the global population.

Geographically, North America held the largest share in the OTT services market in 2020 due to the burgeoning internet penetration in the region. As per the ITU, nearly 88.49% of the North American population used the internet in 2018. Whereas, the Asia-Pacific (APAC) market is expected to observe the fastest growth during the forecast period as a result of the booming population, expanding smartphone user base, and increasing internet penetration in developing countries, such as China and India.

Thus, the expanding smartphone customer base and rising internet penetration will supplement the market growth.

Pubblicato il

Need for Hygienic Work Environment Drives the Professional Hygiene Market

Professional Hygiene Market

The size of the professional hygiene market will grow at a rate of 5.10% by the end of this decade, to touch USD 23,953 million by 2030.

Because of the increase in populace, shift of individuals from urban to rural areas, and surge in tourism actions, the requirement for hygiene upkeep products is increasing in the hospitality industry, which had about 40% share in the industry in the past.

The category comprises of motels, hotels, spas, food service providers, beauty salons, and other spaces where guests’ accommodation and other personal needs are catered to. One of the straightforward things that visitors expect at these places is good cleansing and hygiene.

The main driver for the development of the tissues and napkins category is the snowballing consciousness of hand hygiene in workplaces and increasing occurrence of HAIs. At hotels, hospitals, and offices, tissue and napkins are the most used products for hand drying; so, they had over 81% share in the professional hygiene market in the recent past.

Also, the progressions in the tech of making tissues, advent of organic tissue paper and cutting-edge ways of dispensing, increasing incomes, and initiatives of the government to support public health are driving the development of the industry.

The use of tissues in washrooms because of need, overall Westernization of the washroom culture, snowballing consciousness of hygiene and sanitation, and mounting living standard have augmented the requirement for finest sanitary products, for further ease.

It is due to the rising need for hygienic work environment, the demand for professional hygiene solutions will continue to grow in the years to come as well.

Pubblicato il

Efficacy Testing is Most Demanded in North America

Efficacy Testing Market

The efficacy testing market will reach a value of USD 507 million by 2030, progressing at 6.10% by the end of this decade.

This is because of the advance in the requirement for an advanced quality and competence of biologics and other drugs. Also, the increasing count of guidelines for product approvals is substantial for this industry. The guidelines of the FDA and numerous other national and regional regulatory agencies addressing the safety of pharma and cosmetic products are rather strict.

The increasing acceptance of the QbD approach by pharma and biotech companies for the reason that of the importance of the stability and efficiency of any drug amongst patients and themselves is a key trend in the healthcare industry.

Numerous companies are accepting this method for ensuring that all the sources of variability affecting a procedure are identified, clarified, and managed with suitable measures and for maintaining the drug quality. This allows the finished medicine to reliably meet the predefined performance characteristics from the start.

North America led the industry with about 52%, in 2022, and it will continue like this in the years to come as well. The key reasons for this growth are the high acceptance rate of cutting-edge techniques and diagnostic tools, highest healthcare and R&D spending, and rising outsourcing of testing processes by pharma and cosmetics companies.

Furthermore, the strong existence of the key service providers makes the market lucrative for players and investors. Besides, stringent regulations for drug development in the U.S. and the increasing government funding and initiatives for startups in life sciences are the other factors increasing the requirement for efficacy testing.

Due to the increasing number of regulations for product approvals has a lot to do with the growing demand for efficacy testing all over the world.

Pubblicato il

Enhancing Quality and Safety in Biopharmaceutical Manufacturing with Bioprocess Validation

Bioprocess Validation Market

Maintaining high-quality standards is crucial throughout the bioproduct manufacturing process. This involves eliminating contaminants and impurities from chromatographic media, which can consist of viruses, nucleic acids, endotoxins, cell membranes, aggregates, culture media components, proteins, ligands, product alterations, process chemicals, and inactive microbes.

To ensure the effectiveness of equipment and methods used in manufacturing processes, rigorous scientific validation exercises with thorough documentation are necessary. The FDA’s General Principles of Process Validation guidelines require documented evidence at all stages of bioprocess validation studies to provide a high level of confidence in the intended product quality for consumers.

Bioprocess validation is an integrated process that adheres to FDA, EMA, and other national and international regulations and standards. It aims to verify procedures and ensure compliance with current Good Manufacturing Practices (cGMP). Extensive documentation is required by national and international guidelines to confirm that the process follows standard procedures.

To improve production many drug manufacturers are turning to third-party service providers. The use of disposable technologies during medication development further reduces production costs. Single-use bioreactors have increased process adaptability and significantly reduced the risk of cross-contamination. These advancements benefit the bioprocess validation sector by shortening commercialization timelines and ensuring product reliability.

The COVID-19 pandemic has also had a significant impact on bioprocess validation. The demand for validation services increased during the pandemic as validation became necessary at all stages of drug development to monitor accuracy, safety, and efficiency. Extensive testing and manufacturing of vaccines drove the need for process validation.

Increasing Focus on Extractables/Leachables Testing Services

Bioprocess validation services include extractables/leachables testing, bioprocess residual testing, viral clearance testing, and filtration and fermentation systems testing. Extractables/leachables testing dominates this service segment due to the rising risk of product adulteration and the presence of regulatory guidelines. Prominent guidelines in this area include those from the FDA and current good manufacturing practice guidelines.

Rising Utilization of Filter Elements

Bioprocess validation products encompass filter elements, media containers and bags, freezing and thawing process bags, mixing systems, and bioreactor transfer systems. The usage of filter elements is expected to significantly increase, primarily driven by their essential role in various bioprocessing techniques to ensure the efficacy and safety of biopharmaceutical products at each production step.

The use of bioreactors for manufacturing vaccines, medicines, and other pharmaceutical components is also on the rise. Bioreactors are widely employed in healthcare research for converting in-vitro 2D culture models and suspensions into the 3D form, replicating the natural physiological state at the site.

Growing Importance of Biopharmaceuticals

The increasing prevalence of chronic diseases is driving the demand for biopharmaceuticals, leading to the rapid adoption of bioprocess validation services across the healthcare sector. Infectious diseases, cancer, and neurological disorders are becoming more prevalent, highlighting the significance of biopharmaceuticals.

Many biopharmaceuticals used to treat neurodegenerative disorders are directly administered into the brain, which is not feasible with conventional synthetic agents. Furthermore, advancements in bio-based drugs have resulted in higher survival rates for cancer patients, hepatitis cures, improved arthritis management, and transformed treatment options for various diseases. The rising incidence of such diseases drives the growth in biopharmaceutical use, thereby boosting the development of the bioprocess validation sector.

The bioprocess validation sector in Asia is advancing significantly due to increased government support for pharmaceutical research and development, a growing elderly population, and a rising trend of outsourcing in the region. Moreover, the global bioprocess validation industry is projected to reach a value of USD 835 million by the end of this decade.

Pubblicato il

Cellular Health Screening – Global Industry Insights, Development and Future Analysis

Cellular Health Screening Market

In 2022, the size of the cellular health screening market amounted to USD 2,622.1 million and is projected to rise at a compound annual growth rate of 9.7% until 2030 when it reaches USD 5,512.8 million.

This growth of the market can be credited to the increasing applications of cellular health screening in modified drugs, sensing illnesses at an initial stage, aiding preventive care, and spotting different health-linked issues; the growing count of awareness campaigns; the rising acceptance of telomere performance programs; and the rising occurrence of chronic diseases primarily cancer throughout the globe.

On the basis of test type, the single-test panel category is dominating the industry. This can be credited to its labor productivity, cost-efficiency, and augmented potential for automation.

Among single-panel tests, the need for telomere single-panel tests is projected to advance at the highest rate during the projection period. This can be because these provide precise data, help in calculating the length of telomere, and support in determining cell age.

On the basis of sample type, the urine sample category is estimated to witness the fastest development during the projection period. This is mainly because is it extensively utilized for sensing and handling a huge count of syndromes, like diabetes, kidney diseases, and urinary tract infections.

Furthermore, gathering urine is a convenient and non-invasive technique and it can be done by patients and does not need any equipment or specialist. Furthermore, a urine sample is also utilized for the identification of heavy metals and oxidative stress and cell health studies.

On the basis of the collection site, the hospital’s category grips the largest income share in the industry. This is mainly because of the growing healthcare spending and the existence of a huge count of hospitals throughout the globe, where analysis and treatments are offered instantaneously, and they have progressive diagnostic methods and medicinal specialists for specific tests for the identification of illnesses.

The North American market will continue to hold the world’s top position in cell health screening, valued at USD 2.5 billion by 2030. In the region, this is due to increasing government funding for preventative health care, rapid adoption of new technologies, rising awareness of personalized medicine, and an increased incidence of chronic diseases such as tuberculosis.

In North America, the U.S. industry grips the dominating position, and it will advance at a CAGR of 10% during the projection period. This can be credited to the strong healthcare infrastructure and the presence of a huge count of key companies in the nation.

The key drivers of the cellular health screening industry comprise the growing emphasis on healthy life expectancy, increasing healthcare spending, the rising occurrence of illnesses, and the rising elderly populace.

Pubblicato il

Supervisory Control and Data Acquisition Market Growth and Future Analysis

SCADA Market

The SCADA market will propel at a rate of rate of 7.4% by the end of this decade, to touch USD 16,994 million by 2030. This is credited to the high adoption of Industry 4.0 solutions using SCADA devices, the rising use of software platforms for example IoT and AI, the snowballing requirements for industrial mobility solutions for effective process management, and the increasing growth in WSNs.

The increase in the development of Industry 4.0 across both manufacturing and process industries quickens the growth of the industry. They employ these services as part of their digitalization plans. As a result of their high level of tech acceptance, industries are facing a high need to update a present SCADA system. Therefore, the requirement for such systems is increasing, because of the digitization of production procedures using sensors and info devices.

With its cutting-edge competences to lay emphasis more on productivity, SCADA makes a positive change. Even a positive IoT report generation contributes strongly to improve decision-making and the making of new strategies for improving business performance.

North America SCADA market has a significant share. This is because of the steady power management of SCADA, enormous investment in technologies, the growing industrial sector, and the growing acceptance of automation tech.

Likewise, automation tech acceptance is supported by the increasing industrial sector in the region. Furthermore, the requirement for supervisory control and data attainment products would be boosted by governments’ augmented focus on smart city development, as these systems are used by smart cities to advance transport and wastewater management.

It is because of the rapid growth in big data and analytics all over the world, the demand for SCADA is on the rise.

Pubblicato il

Fill-Finish Manufacturing Market is Led by the APAC Region

Fill Finish Manufacturing Market

The fill-finish manufacturing market made a revenue of USD 10.1 billion in 2023, and it will touch a value of USD 20.7 billion by 2030, powering at a rate of 10.9% by the end of this decade, powered by the increasing requirement for injectables, as well as biologics and modified medicines.

This procedure plays a significant role in the pharma and biotech sectors by being the last stage in the production process, wherein biologic and synthetic drugs are dispensed into their containers and packed for distribution.

On the basis of the product, consumables led the industry with a share of 65%, in 2023, and it will be like this in the future as well. Consumables put to use in in the fill−finish procedure comprise vials, cartridges, syringes, caps, seals, stoppers, and filters.

Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=fill-finish-manufacturing-market-report

They are often single-use things, meaning they can be used once and then discarded. This trend of single-use consumables has become popular as a result of the growing requirement to decrease the risk of cross infection, attain faster changeovers amid diverse drug products, and minimalize capital investments and cost of maintenance.

Consequently, the requirement for consumables has augmented considerably, therefore powering the industry.

The fill-finish manufacturing market is powered by the growing requirement for injectable drugs. These drugs can be managed at once into the bloodstream or tissue with the help of injections. They are employed for the prevention, treatment, and management of numerous diseases, such as cancers, diabetes, autoimmune issues, and infections.

Such ailments need lasting treatment, often connecting the regular administration of injectable medications. As the existence of these diseases continues to increase, the requirement for parental drugs will also rise, thus contributing to the rise in the requirement for fill-finish services.

APAC was the leader of the pack, with a share of about 45%, in 2023, and this trend will continue in the years to come as well. The main region for this is that the region has a strong presence of pharma and biotech companies.

China, Japan, India, and South Korea are the hubs for pharma production and R&D activities. These have well-established pharma infra, a large and skilled workforce, and advantageous guidelines of the government supporting the development of related businesses.

Furthermore, more than a few biotech and pharma companies from Europe and North-America outsource their final-stage production process to firms based in the region on contract.

It is because of the growing demand for injectables and continuous advancements in technology all over the world, the demand for fill-finish manufacturing is on the rise, This trend will continue in the years to come as well.